Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis

These findings suggest a possible way to target a weakness in some triple-negative breast cancers. They also raise the possibility that a tumor’s p53 status could help identify who might benefit from this drug combination. These are preclinical results: further research is needed to determine whether the approach is safe and effective for patients. This work was done in collaboration with Jill Bargonetti at Hunter College in NYC. She was the original discoverer of mutp53 as an activated gene product.

Make it stand out

Whatever it is, the way you tell your story online can make all the difference.